Fuji Announces Marketing Agreement with Sanat
"We envision our collaboration and cooperation within the sphere of Microalgae and related product marketing as an augmented step in more effectively reaching the customer base in North America," said Amit Sharma
1/17/2011 --- Fuji Health Science, Inc. a wholly owned subsidiary of Fuji Chemical Industry Co., Ltd announced the conclusion of its marketing agreement with Sanat Products Ltd, India involving the strategic placement of spirulina products within the North American market.
Sanat is a broad based producer of Herbal Extract, natural health care products and herbal Pharmaceuticals. Applying the rigors of pharmaceutical quality to the natural product sector insures a level of excellence expected by consumers worldwide.
Fuji is similarly based in pharmaceuticals along with the development and production of high performing excipients as well as unique nutritional ingredients.
Both companies are involved in the cultivation of microalgae for natural human health benefit. Fuji is a world leader in the production of natural astaxanthin from the single cell microalgae, Haematococcus pluvialis and Sanat is a major producer of Organic spirulina.
Charles DePrince, president of Fuji Health said, "I see a synergy between the technologies of both companies that when combined has the potential to expand the scope of our product offerings in the market."
"We envision our collaboration and cooperation within the sphere of Microalgae and related product marketing as an augmented step in more effectively reaching the customer base in North America," said Amit Sharma, General Manager – International Business of Sanat Products Limited.
